相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma
Ru Jia et al.
ONCOLOGY LETTERS (2021)
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
Alessandro Dal Maso et al.
CLINICAL LUNG CANCER (2020)
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib
Jun Zhao et al.
LUNG CANCER (2020)
Independent prognostic value of ultra-sensitive quantification of tumor pretreatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Michele Beau-Faller et al.
LUNG CANCER (2020)
The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art
D. Franceschini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI
Oscar S. H. Chan et al.
LUNG CANCER (2020)
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
Yasir Y. Elamin et al.
CLINICAL LUNG CANCER (2019)
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
Yanxin Chen et al.
BMC CANCER (2019)
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
Manon Kissel et al.
BMC CANCER (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
Yi-Long Wu et al.
CLINICAL LUNG CANCER (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients
Shun-Ichiro Kageyama et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
Helen Mann et al.
CLINICAL DRUG INVESTIGATION (2018)
Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
Takashi Seto et al.
ONCOLOGY AND THERAPY (2018)
Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment
Wenbin Li et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
C. Mayo-de-las-Casas et al.
ANNALS OF ONCOLOGY (2017)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer
Marta Scorsetti et al.
BREAST (2016)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez et al.
LANCET ONCOLOGY (2016)
Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Meghan Campo et al.
ONCOLOGIST (2016)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok et al.
CLINICAL CANCER RESEARCH (2015)
Emerging paradigms in targeted treatments for Asian patients with NSCLC
E-E Ke et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy
Hani Al-Halabi et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer
Ting-Shi Su et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma
Maobin Meng et al.
DRUG DISCOVERIES AND THERAPEUTICS (2015)
Gefitinib Combined With Stereotactic Radiosurgery in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Zhen Wang et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2014)
Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer
Sivan M. Bokobza et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
J. L. Kuiper et al.
LUNG CANCER (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line-Is There a Difference?
Tony Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE PERFORMANCE OF STEREOTACTIC BODY RADIATION THERAPY
Louis Potters et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Kyle E. Rusthoven et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
